The relationship between Parkinson’s disease and glaucoma
巴金森氏症（Parkinson’s Disease, PD）與青光眼（Glaucoma）看似是兩個截然不同的疾病——一個關乎大腦運動控制，一個關乎視力損失——但醫學界研究發現，這兩者之間其實存在著深層的神經退化性聯繫。
簡單來說，它們就像是「住在不同器官的親戚」，共享了某些致病的生物藍圖。
1. 共同的神經退化本質
巴金森氏症主要是大腦中多巴胺神經元的流失，而青光眼則是視網膜上**視網膜神經節細胞（RGCs）**的凋亡。
- 細胞凋亡機制： 兩者都涉及粒線體功能障礙、氧化壓力以及發炎反應。
- 蛋白質異常： 研究發現，在某些青光眼患者的視網膜中，也觀察到了與巴金森氏症相關的異常蛋白質沉積（如 $\alpha$-突觸核蛋白）。
2. 「多巴胺」的關鍵角色
我們通常認為多巴胺只跟大腦的快樂或運動有關，但其實視網膜內也含有多巴胺神經元。
- 視覺調節： 視網膜中的多巴胺負責調節對比敏感度、顏色辨識及光適應。
- 交互影響： 巴金森氏症患者因為全身性多巴胺水平下降，常會出現視網膜變薄的現象。這種變薄的表現與青光眼造成的神經受損在臨床影像上非常相似，有時容易造成誤診或漏診。
3. 藥物使用的潛在風險（非常重要）
如果您或親友同時患有這兩種疾病，必須特別注意巴金森氏症的藥物對眼壓的影響：
- 抗膽鹼藥物（Anticholinergics）： 常見於治療巴金森氏症的震顫。這類藥物可能會導致散瞳，進而引發急性閉鎖性青光眼。
- 左旋多巴（L-Dopa）： 雖然是治療 PD 的首選藥物，但在極少數情況下可能與眼壓波動有關。
⚠️ 溫馨提醒： 若您正在服用巴金森氏症藥物且被診斷出有「窄角型青光眼」，務必主動告知神經內科與眼科醫師，以便調整用藥。
4. 臨床上的關聯數據
根據近年的大數據追蹤研究：
- 巴金森氏症患者罹患青光眼的機率，通常比一般同齡人稍高。
- 同樣地，某些青光眼患者在未來出現運動障礙或發展成 PD 的風險也略有提升。
這顯示了這兩者可能擁有共同的基因易感性。
我可以如何協助您？
這兩者的關係非常微妙，如果您是幫長輩詢問，或者自己有相關疑慮，您是否想了解具體的「用藥安全檢查清單」，或是想知道巴金森氏症患者日常該如何進行眼部護理？
Parkinson’s disease (PD) and glaucoma appear to be two distinct diseases—one affecting motor control in the brain, the other causing vision loss—but medical research has revealed a deep neurodegenerative link between them.
Simply put, they are like “relatives living in different organs,” sharing certain pathogenic biological blueprints.
1. Shared Neurodegenerative Nature
Parkinson’s disease primarily involves the loss of dopamine neurons in the brain, while glaucoma is caused by the apoptosis of retinal ganglion cells (RGCs) in the retina.
- Mechanisms of Apoptosis: Both involve mitochondrial dysfunction, oxidative stress, and inflammatory responses.
- Protein Abnormalities: Studies have found abnormal protein deposits (such as β-synuclein) associated with Parkinson’s disease in the retinas of some glaucoma patients.
2. The Key Role of Dopamine
We often think of dopamine only as being related to pleasure or movement in the brain, but dopamine neurons are also present in the retina.
- Visual Accommodation: Dopamine in the retina is responsible for regulating contrast sensitivity, color perception, and light adaptation.
- Interactions: Parkinson’s disease patients often experience retinal thinning due to a systemic decrease in dopamine levels. This thinning is very similar to the nerve damage caused by glaucoma in clinical imaging, sometimes leading to misdiagnosis or missed diagnosis.
3. Potential Risks of Medication Use (Very Important)
If you or a loved one has both Parkinson’s disease and glaucoma, you must pay special attention to the effects of Parkinson’s medications on intraocular pressure:
- Anticholinergics: Commonly used to treat tremor in Parkinson’s disease. These medications may cause mydriasis, potentially triggering acute occlusive glaucoma.
- Levodopa (L-Dopa): While it’s the first-line treatment for Parkinson’s disease (PD), it may be associated with intraocular pressure fluctuations in rare cases.
⚠️ Important Reminder: If you are taking Parkinson’s medication and have been diagnosed with narrow-angle glaucoma, please inform your neurologist and ophthalmologist so that your medication can be adjusted.
4. Clinical Correlation Data
According to recent large-scale data tracking studies:
- Parkinson’s patients generally have a slightly higher chance of developing glaucoma than their peers.
- Similarly, some glaucoma patients have a slightly increased risk of developing motor impairments or PD in the future.
This suggests that these two conditions may share a common genetic susceptibility.
How Can I Help You?
The relationship between these two is very delicate. If you are asking on behalf of an elder, or if you yourself have related concerns, would you like to know the specific “medication safety checklist,” or want to know how Parkinson’s disease patients should perform daily eye care?
發佈留言